Trazodone is not a barbiturate. It belongs to an entirely different class of medication called serotonin antagonists and reuptake inhibitors, or SARIs. The two drugs differ in their chemical structure, how they work in the brain, their safety profile, and their legal classification. The confusion likely comes from the fact that both trazodone and barbiturates can cause sedation, but the similarities end there.
How Trazodone Works
Trazodone is a triazolopyridine derivative, a chemical structure unrelated to barbituric acid (the backbone of all barbiturates). Its primary action is on the serotonin system. It blocks the reuptake of serotonin, keeping more of it available between nerve cells, while also blocking specific serotonin receptor subtypes (5-HT2A and 5-HT2C). On top of that, it blocks histamine receptors and certain adrenaline receptors, which is largely what makes it sedating.
This combination of effects sets trazodone apart from SSRIs and other common antidepressants. Because it blocks the same serotonin receptors that SSRIs overstimulate, trazodone is less likely to cause sexual dysfunction, insomnia, or anxiety, side effects frequently reported with other antidepressants.
The FDA has approved trazodone for one indication: major depressive disorder in adults. However, it is widely prescribed off-label at lower doses for sleep. Its sedating properties made it one of the most commonly prescribed medications for insomnia in the U.S., even though the evidence supporting that use is surprisingly thin. A 2017 guideline from the American Academy of Sleep Medicine found no evidence that trazodone improves sleep quality and recommended against using it for insomnia. Research also suggests that whatever initial sleep benefit trazodone provides tends to fade within about two weeks.
How Barbiturates Work
Barbiturates operate through a completely different mechanism. They enhance the activity of GABA, the brain’s main inhibitory chemical messenger, by binding to GABA-A receptors. At low doses, they make the brain’s natural calming signals last longer. At higher doses, they can directly activate those receptors on their own, essentially forcing sedation whether or not the brain is sending a calming signal. This is what makes barbiturates so effective as sedatives and anti-seizure drugs, and also what makes them dangerous.
Common barbiturates include phenobarbital (still used for epilepsy) and secobarbital (historically used for sleep). They were once the standard treatment for anxiety and insomnia, but their use has dropped dramatically because safer alternatives exist. The core problem with barbiturates is their narrow therapeutic index: the difference between a dose that works and a dose that can kill you is small.
Safety and Overdose Risk
This is one of the most important distinctions between the two. Barbiturates carry a high risk of fatal overdose, which is a major reason they fell out of favor for treating insomnia and anxiety. Respiratory depression, where breathing slows to a dangerous level, is the primary cause of death in barbiturate overdoses.
Trazodone has a much wider safety margin. A review of 88 trazodone overdose cases reported to the manufacturer found that 73 resulted in uneventful recovery. The nine deaths that occurred all involved trazodone taken alongside other drugs or alcohol. A separate analysis of 206 overdose exposures to trazodone alone recorded zero deaths. When taken by itself in overdose, trazodone appears to have limited toxicity. That said, mixing trazodone with alcohol, barbiturates, or other central nervous system depressants can amplify sedation and increase danger, a warning included on the FDA label.
Controlled Substance Status
Barbiturates are classified as controlled substances by the DEA because of their potential for dependence and abuse. Secobarbital, for example, is a Schedule II substance, the same category as oxycodone and fentanyl. Phenobarbital is Schedule IV.
Trazodone does not appear on the DEA’s controlled substances list at all. It is a standard prescription medication with no special restrictions on refills or prescribing. While you can develop some physical dependence on trazodone over time (gradual tapering is recommended if you’ve been taking it long-term), its abuse potential is considered low.
Why the Confusion Happens
People often associate any medication that causes drowsiness with barbiturates or “sleeping pills” from an older era. Trazodone’s heavy use as a sleep aid reinforces this mental link. Both barbiturates and trazodone can make you feel groggy, and both interact dangerously with alcohol. But the resemblance is superficial. They act on different neurotransmitter systems (serotonin versus GABA), have different chemical structures, carry very different overdose risks, and are regulated differently by federal law.
If you’re taking trazodone for sleep and wondering whether it carries the same risks as a barbiturate, the short answer is no. Its side effect profile is real but far milder. Common issues include daytime drowsiness, dizziness, and dry mouth. A 2022 network analysis found that for acute insomnia, the chance of experiencing harm from trazodone was roughly equal to the chance of experiencing a benefit, with about 1 in 12 people helped and 1 in 12 harmed by side effects. That’s a modest trade-off, but it’s a world apart from the life-threatening risks barbiturates carry.